ClinicalTrials.gg
RecruitingNCT07014449Updated Oct 16, 2026

Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of WBC100 QD in AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia and Refractory Acute Myeloid Leukemia, sponsored by Hangzhou Weben Pharma Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Hangzhou Weben Pharma Co., Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2024, registered May 2025).
  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 16, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
264th of 433
36 · median 50
Started
2024
with 67 others
Phase 1
121 of 473
69 open now
Primary completion
2026-12
later than 134 of 288 live
Registered
378th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 264th largest by planned enrollment of the 433 interventional ones that give a count, is one of 68 that started in 2024, is one of 121 in phase 1, reaches primary completion later than 134 of the 288 other live ones, and was the 378th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML). The main questions it aims to answer are:

  • What is the safety and tolerability profile of WBC100 in R/R AML patients?
  • Can WBC100 effectively induce remission in R/R AML patients?

Participants will:

  • Take WBC100 capsules orally once daily in 28-day treatment cycles;
  • Undergo regular safety assessments, including adverse event monitoring and laboratory tests;
  • Provide blood samples for pharmacokinetic (PK) analysis;
  • Have their remission status and efficacy evaluated according to the ELN2022 criteria.
03

Conditions studied

  • AML (Acute Myelogenous Leukemia
  • Relapsed Acute Myelogenous Leukemia
  • Refractory Acute Myeloid Leukemia
  • Hematologic Malignancy
  • C-Myc
  • Adult Acute Myeloid Leukemia

Keywords

  • c-Myc
  • Molecular glue
  • Acute Myelogenous Leukemia
  • Relapsed and Refractory Acute Myelogenous Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Signed and compliance with study procedures;
  • 2. Male or female participants aged ≥18 years at the time of consent;
  • 3. Diagnosis of acute myeloid leukemia (R/R AML) according to the 2016 World Health Organization (WHO) classification;
  • 4. PS 0-2;
  • 5. ≥3 months;
  • 6. Adequate bone marrow reserve and organ function as defined below:

    1. Bone marrow reserve: Peripheral WBC \< 25 × 10⁹/L (leukocyte-reducing agents are allowed, with a of at least 5 half-lives prior to study drug administration);
    2. Coagulation: (INR) ≤ 2;
    3. Hepatic function: Total (TBIL) ≤ 1.5 × ; and AST ≤ 2.5 × ULN. In cases of hepatic involvement: ALT or AST ≤ 5 × ULN, and TBIL ≤ 3 × ULN;
    4. Renal function: ≥60 mL/min (Cockcroft-Gault), or serum creatinine ≤1.5 × ULN;
    5. Cardiac function: (LVEF) ≥50%; ≤450 ms for males, ≤470 ms for females.
  • 7. Female participants of and fertile male participants with partners of childbearing potential must use medically approved during treatment and for 6 months after the final dose.

Exclusion criteria

Exclusion Criteria:

  • 1. Known to WBC100 capsules or any of their ;
  • 2. Diagnosis of acute promyelocytic leukemia (APL);
  • 3. Diagnosis of mixed phenotype acute leukemia, chronic myeloid leukemia in blast crisis, or AML transformed from myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN);
  • 4. Subjects with relapse after HSCT, grade ≥ 2 acute , extensive chronic GVHD requiring therapy, or autologous HSCT within the past 90 days;
  • 5. Subjects who have undergone major surgery, have active ulcers, or have unhealed wounds within 28 days prior to the first dose;
  • 6. Received other drugs or treatments within 28 days prior to the first administration, or are still within the safety follow-up period of another clinical trial;
  • 7. Subjects with a history of severe cardiovascular or cerebrovascular conditions, including but not limited to:

    1. Significant arrhythmias or conduction disorders (e.g., ventricular arrhythmias, Grade II-III AV block);
    2. Thromboembolic events requiring anticoagulation or presence of vena cava filter;
    3. Class III-IV heart failure;
    4. Poorly controlled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg despite treatment).
  • 8. Evidence of severe or uncontrolled systemic diseases, such as effusions, poorly controlled diabetes, or significant disorders of the psychiatric, neurological, cardiovascular, respiratory, endocrine, gastrointestinal, hepatic, or renal systems;
  • 9. History or presence of immunodeficiency, disease requiring systemic immunosuppressants, or organ transplantation;
  • 10. Congestive heart failure, aortic dissection, stroke (excluding lacunar infarct), unstable angina, myocardial infarction, bypass surgery, or pulmonary embolism within 180 days prior to first dosing;
  • 11. Known risk factors for , including congenital long QT syndrome or drug-induced arrhythmia history;
  • 12. Positive for syphilis antibodies, , active infection (HBsAg+ or HBcAb+ with HBV DNA ≥1000 IU/mL), or active infection (HCV Ab+ with detectable HCV RNA);
  • 13. Active infection requiring systemic treatment, including uncontrolled bacterial, viral, or fungal infections;
  • 14. Gastrointestinal conditions preventing oral drug intake or absorption, such as severe vomiting, chronic diarrhea, intestinal stoma, malabsorption, or inability to swallow;
  • 15. Use of strong CYP450 inhibitors/inducers that cannot be stopped ≥7 days before dosing;
  • 16. Receipt of monoclonal antibodies, ADCs, radiotherapy within 28 days (14 days for localized radiotherapy), cytotoxic chemotherapy, targeted small molecules within 14 days or 5 half-lives, or CAR-T therapy within 100 days;
  • 17. Receipt of any live or attenuated vaccines (e.g., influenza, varicella) within 28 days;
  • 18. History of other within 2 years, except adequately treated basal cell carcinoma, carcinoma in situ of cervix or breast, or squamous cell carcinoma of the skin;
  • 19. History of psychiatric or neurological disorders that may interfere with protocol compliance;
  • 20. Inability to tolerate venous blood draws;
  • 21. Pregnant or breastfeeding women, or women with positive serum hCG during screening;
  • 22. Any condition deemed by the investigator to make the subject unsuitable for study participation.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    WBC100 Dose Escalation Cohort

    Participants will take WBC100 capsules orally once daily in 28-day cycles. This arm includes a dose-escalation phase using an accelerated titration combined with the traditional '3+3' design. After a single-patient observation at 0.5 mg, three patients will be enrolled per cohort at each subsequent dose level (1.0, 1.5, 2.0, 2.5, and 3.0 mg). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal.

    Drug: WBC100 QD

  • Experimental
    WBC100 2.5 mg QD Dose Expansion Cohort

    Participants will receive 2.5 mg of the investigational drug orally once daily (QD) during the dose expansion phase.

    Drug: WBC100 QD

Interventions

  • DrugWBC100 QD

    WBC100 will be administered orally as capsules once daily in 28-day cycles.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of dose-limiting toxicities (DLTs)

    Evaluated according to NCI-CTCAE version 5.0.

    Time frame: During the first treatment cycle (28 days)

  2. Incidence and severity of treatment-emergent adverse events (TEAEs)

    Includes lab abnormalities, physical exam findings, vital signs, and ECG changes.

    Time frame: From first dose to 28 days after the last dose

  3. Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)

    Based on observed DLTs.

    Time frame: 28 days

Secondary outcomes

  1. Cmax

    Peak plasma concentration after one dose, measured using a validated LC-MS/MS method

    Time frame: 28 days

  2. Tmax

    Time to peak plasma concentration after one dose

    Time frame: 28 days

  3. AUC0-t

    Area under the plasma concentration versus time curve after one dose and multiple dose; time range from 0 to last point when plasma concentration is detectable

    Time frame: 28 days

  4. AUC0-inf

    Area under the plasma concentration versus time curve; time range from 0 to infinity

    Time frame: 28 days

  5. T1/2

    Half-life period

    Time frame: 28 days

  6. λz

    Elimination rate constant

    Time frame: 28 days

  7. CL/F

    Apparent clearance

    Time frame: 28 days

  8. Vz/F

    Apparent volume of distribution

    Time frame: 28 days

  9. Cmax, ss

    Steady peak plasma concentration after multiple dose

    Time frame: 28 days

  10. Cmin, ss

    Steady minimal plasma concentration after multiple dose

    Time frame: 28 days

  11. Cavg

    Steady average plasma concentration after multiple dose

    Time frame: 28 days

  12. Tmax, ss

    Time to steady peak plasma concentration after multiple dose

    Time frame: 28 days

  13. CLss/F

    Steady apparent clearance

    Time frame: 28 days

  14. Vss/F

    Steady apparent volume of distribution

    Time frame: 28 days

  15. ARCmax

    Peak concentration cumulative coefficient

    Time frame: 28 days

  16. ARAUC

    AUC cumulative coefficient

    Time frame: 28 days

  17. DF

    Degree of fluctuation (DF) will be calculated as (Cmax,ss - Cmin,ss) / Cavg,ss × 100%, where Cmax,ss is the maximum plasma concentration at steady state, Cmin,ss is the minimum plasma concentration at steady state, and Cavg,ss is the average plasma concentration over the dosing interval at steady state.

    Time frame: 28 days

  18. Duration of response (DOR)

    The period from the first evaluation of complete response (CR) or partial response (PR) to the first evaluation of progressive disease (PD) or death of any cause

    Time frame: 2 years

  19. Event-free survival period (EFS)

    EFS, defined as the time from the start of the subject's enrollment to the occurrence of any event (treatment failure/relapse after CR, CRh or CRi/permanent termination of treatment for any reason/death from any cause), whichever occurs first.

    Time frame: 2 years

  20. Overall survival (OS)

    From date of treatment start until the date of death due to any cause.

    Time frame: 2 years

Other outcomes

  1. Exploratory biological analysis of bone marrow aspirate samples

    Bone marrow aspirate samples will be collected at each tumor assessment, when feasible, for exploratory biological analyses such as C-Myc protein expression.

    Time frame: Cycle 1 (28 days)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 182 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 25 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jun 2026 → Dec 2026 and completion Jun 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Jun 11, 2025
StartActual
Nov 3, 2024
Primary completionEst.
Dec 2026was Jun 2026
CompletionEst.
Dec 2026was Jun 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Dec 2026
Oct 16, 2026
Study completion
Jun 2026→Dec 2026
Oct 16, 2026
Enrollment
18→36
Oct 16, 2026
Interventions
Arm changed WBC100 Capsules→WBC100 Dose Escalation Cohort. Arms added: WBC100 2.5 mg QD Dose Expansion Cohort
Oct 16, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionCmax: how it is measured was reworded
  • DescriptionDF: how it is measured was reworded
Oct 16, 2026
Contact
Study contact changed: b•••@webenpharma.com · •••2331→s•••@webenpharma.com · •••1260; b•••@webenpharma.com · •••3516→m•••@webenpharma.com · •••1169. See the current contact
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Jun 2026→Dec 2026
    Study completion Jun 2026→Dec 2026
    Enrollment 18→36
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionCmax: how it is measured was reworded
    • DescriptionDF: how it is measured was reworded
    Interventions Arm changed WBC100 Capsules→WBC100 Dose Escalation Cohort. Arms added: WBC100 2.5 mg QD Dose Expansion Cohort
    Contact Study contact changed: b•••@webenpharma.com · •••2331→s•••@webenpharma.com · •••1260; b•••@webenpharma.com · •••3516→m•••@webenpharma.com · •••1169. See the current contact
    + 4 other changes: index terms, verification date, design details and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07014449
Lead sponsor
Hangzhou Weben Pharma Co., Ltd
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Nov 3, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Wu Shuigao, M.S
Contact
sgwu@webenpharma.com
+86-18761861260
Zheng Meng, PM
Contact
mzheng@webenpharma.com
86-15267131169

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion